Skip to main content
SpringerLink
Log in

Cytoreductive surgery for ovarian cancer

  • Chapter
Ovarian Cancer

Part of the book series: Cancer Treatment and Research ((CTAR,volume 23))

Abstract

Ovarian cancer presents a unique surgical challenge because of its mode of dissemination. Early in its course, epithelial ovarian cancer is usually asymptomatic, and even small primary tumors may exfoliate cells which implant throughout the peritoneal cavity. At the time of diagnosis, approximately 70–80% of epithelial tumors have spread beyond the ovaries. Germ cell tumors may also disseminate in this manner, but because they are more rapidly growing, they are frequently symptomatic, so are more commonly diagnosed early.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Silberman AW: Surgical debulking of tumors. Surg Gynecol Obstet 155:577, 1982.

    PubMed  CAS  Google Scholar 

  2. Skipper HE, Schabel FM Jr, Wilcox WS: Experimental evaluation of potential anticancer agents XII: On the criteria and kinetics associated with ‘curability’ or experimental leukemia. Cancer Chemother Rep 35:1–111, 1964.

    PubMed  CAS  Google Scholar 

  3. De Vita VT: The relationship between tumor mass and resistance to chemotherapy. Implications for surgical adjuvant treatment of cancer. Cancer 51:1209, 1983.

    Article  Google Scholar 

  4. Gullino PM, Grantham FH: Studies on the exchange of fluids between host and tumor. II. The blood flow of hepatomas and other tumors in rats and mice. J Natl Cancer Inst 27:1465–1491, 1961.

    PubMed  CAS  Google Scholar 

  5. Gullino PM, Clark SH, Grantham FH: The interstitial fluid of solid tumors. Cancer Research 24:780–794, 1964.

    PubMed  CAS  Google Scholar 

  6. West GW, Weichselbaum R, Little JB: Limited penetration of methotrexate into human osteosarcoma spheroids as a proposed model for solid tumor resistance to adjuvant chemotherapy. Cancer Research 40:3665, 1980.

    PubMed  CAS  Google Scholar 

  7. Tannock I: Cell kinetics and chemotherapy. A critical review. Cancer Treat Rep 62(8): 1117, 1978.

    PubMed  CAS  Google Scholar 

  8. Mendelsohn ML: Autoradiographic analysis of cell proliferation in spontaneous breast cancer of C3H mouse. III. The growth fraction. J Natl Cancer Inst 28:1015, 1962.

    PubMed  CAS  Google Scholar 

  9. Skipper HE: Thoughts on cancer chemotherapy and combination modality therapy (1974). JAMA 230(7): 1033, 1974.

    Article  PubMed  CAS  Google Scholar 

  10. Goldie JH, Coldman AJ: A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63:1727, 1979.

    PubMed  CAS  Google Scholar 

  11. De Vita VT: Cell kinetics and the chemotherapy of cancer. Cancer Chemother Rep 3(2): 23, 1971.

    Google Scholar 

  12. Morton DL: Changing concepts in cancer surgery; surgery as immunotherapy. Am J Surg 135:367, 1978.

    Article  PubMed  CAS  Google Scholar 

  13. Khoo SK, Tillack SV, Mackay EV: Cell-mediated immunity: Effects of female genital tract cancer, pregnancy, and immunosuppressive drugs. Aust NZ J Obstet Gynaecol 15:156, 1975.

    Article  Google Scholar 

  14. Pattillo RA, Ruckert ACF, Story MT, et al.: Immunodiagnosis in ovarian cancer: Blocking factor activity. Am J Obstet Gynecol 133:791, 1979.

    PubMed  CAS  Google Scholar 

  15. Griffiths CT: Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Mong 42:101, 1975.

    CAS  Google Scholar 

  16. Griffiths CT, Parker LM, Fuller AF: Role of cytoreductive surgical treatment in the management of advanced ovarian cancer. Cancer treat Rep 63:235, 1979.

    PubMed  CAS  Google Scholar 

  17. Day TG Jr, Smith JP: Diagnosis and staging of ovarian cancer. Semin Oncol 2:217–222, 1975.

    PubMed  Google Scholar 

  18. Smith JP, Day TG Jr: Review of ovarian cancer at the university of Texas Systems Cancer Center, M.D. Anderson Hospital and Tumor Institute. Am J Obstet Gynecol 135:984, 1979.

    PubMed  CAS  Google Scholar 

  19. Hudson CN, Chir M: Surgical treatment of ovarian cancer. Gynecol Oncol 1:370–378, 1973.

    Article  Google Scholar 

  20. Hacker NF, Berek JS, Lagasse LD: Gastrointestinal surgery in gynecologic oncology. In Gynecologic Oncology. Edited by Knapp RC, Berkowitz RS. Macmillan and Co., New York, NY. In press.

    Google Scholar 

  21. Berek JS, Hacker NF, Lagasse LD, et al.: Lower urinary tract resection as part of cytoreductive surgery for ovarian cancer. Gynecol Oncol 13:87, 1982.

    Article  PubMed  CAS  Google Scholar 

  22. Hacker NF, Berek JS, Lagasse LD, Nieberg RK, Elashoff RM: Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 61:413–420, 1983.

    PubMed  CAS  Google Scholar 

  23. Wharton JT, Herson J: Surgery for common epithelial tumors of the ovary. Cancer 48:582, 1981.

    Article  PubMed  CAS  Google Scholar 

  24. Hansen MB, Powell DE, Donaldson ES, et al.: Treatment of epithelial ovarian carcinoma by surgical debulking followed by single alkylating agent chemtherapy. Gynecol Oncol 10:337, 1980.

    Article  Google Scholar 

  25. Stehman FB, Ehrlich LH, Einhorn LH, Williams SD, Roth LM: Long term follow-up and survival in Stage III–IV epithelial ovarian cancer treated with cis-dichlorodiamine platinum, adriamycin and cyclophosphamide (PAC). Proc Amer Soc Clin Oncol. Abstract C-573, 1983.

    Google Scholar 

  26. Wharton JT, Rutledge F, Smith JP, et al.: Hexamethylamine: An evaluation of its role in the treatment of ovarian cancer. Am J Obstet Gynecol 133:833, 1979.

    PubMed  CAS  Google Scholar 

  27. Young RC, Chabner BA, Hubbard SP, et al.: Advanced ovarian adenocarcinoma. N Engl J Med 299:1261, 1978.

    Article  PubMed  CAS  Google Scholar 

  28. Schwartz PE, Smith JP: Second-look operations in ovarian cancer. Obstet Gynecol 138:1124–1130, 1980.

    CAS  Google Scholar 

  29. Greco FA, Julian CG, Richardson RI, et al.: Advanced ovarian cancer: Brief intensive combination chemotherapy and second-look operation. Obstet Gynecol 58:199, 1981.

    PubMed  CAS  Google Scholar 

  30. Ehrlich CE, Einhorn L, Williams SD, Morgan J: Chemotherapy for Stage III–IV epithelial ovarian cancer with cis-dichlorodiaminoplatinum (11), adriamycin, and cyclophosphamide: A preliminary report. Cancer Treat Rep 63:281, 1979.

    PubMed  CAS  Google Scholar 

  31. Edwards CL, Herson J, Gershenson DM, Copeland LJ, Wharton JT: A prospective randomized clinical trial or melphelan and cis-platinum versus hexamethylmelamine, adriamycin and cyclophosphamide in advanced ovarian cancer. Gynecol Oncol 15:261, 1983.

    Article  PubMed  CAS  Google Scholar 

  32. Castaldo TW, Petrilli ES, Ballon SC, et al.: Intestinal operations in patients with ovarian carcinoma. Am J Obstet Gynecol 139:80, 1981.

    PubMed  CAS  Google Scholar 

  33. Blythe JG, Wahl TP: Debulking surgery: Does it increase the quality of survival. Gynecol Oncol 14:396, 1982.

    Article  PubMed  CAS  Google Scholar 

  34. Philips BP, Buchsbaum HJ, Lifshitz S: Re-exploration after treatment for ovarian carcinoma. Gynecol Oncol 8:339, 1979.

    Article  Google Scholar 

  35. Raju KS, McKinna JA, Barker GH, Wiltshaw E, Jones JM: Second-look operations in the planned management of advanced ovarian carcinoma. Am J Obstet Gynecol 144:650, 1982.

    PubMed  CAS  Google Scholar 

  36. Berek JS, Hacker NF, Lagasse LD, Nieberg RK, Elashoff RM: Survival of patients following secondary cytoreductive surgery in ovarian cancer. Obstet Gynecol 61:189, 1983.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Neville F. Hacker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jonathan S. Berek
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Internal Medicine Section of Hematology & Oncology, University of Arizona Health Sciences Center, Tucson, Arizona, USA

    David S. Alberts

  2. Department of Obstetrics & Gynecology, University of Arizona Health Sciences Center, Tucson, Arizona, USA

    Earl A. Surwit

Rights and permissions

Reprints and permissions

Copyright information

© 1985 Martinus Nijhoff Publishers, Boston

About this chapter

Cite this chapter

Hacker, N.F., Berek, J.S. (1985). Cytoreductive surgery for ovarian cancer. In: Alberts, D.S., Surwit, E.A. (eds) Ovarian Cancer. Cancer Treatment and Research, vol 23. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2561-1_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-2561-1_4

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4612-9609-6

  • Online ISBN: 978-1-4613-2561-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation